Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3

Not to mention the expectation of commercial supply of Jelli-Grow in mid-2023.
I think it's interesting in the Cash Flow sheet that they've only got 1.85 quarters of funding remaining, and have not said that they're planning on a cash raise but instead "the company is confident it will have access to sufficient capital when needed".

R&D tax rebate due soon, second pilot spin with some sales by end of Feb/early March.
Their R&D spend is relatively low compared to other biotechs, which also means their rebate won't be a big payday. It's going to be dependent on the revenue of the next pilot spin sales whether they will need to do a cash raise by the next quarter.